Postural Orthostatic Tachycardia Syndrome (POTS) is defined by an excessive heart rate increase — 30 beats per minute or more within 10 minutes of standing, or a sustained rate above 120 bpm — in the absence of orthostatic hypotension. It affects an estimated 1–3 million people in the United States, predominantly women of reproductive age. The vagus nerve sits at the centre of the autonomic machinery that fails in POTS, though the condition is more complex than simple vagal weakness.
What Happens When You Stand
Standing shifts roughly 500–700 mL of blood into the lower extremities and splanchnic circulation within seconds. In a healthy autonomic nervous system, baroreceptors in the carotid sinus and aortic arch detect the drop in central blood pressure and trigger a rapid sympathetic response: peripheral vasoconstriction, increased cardiac contractility, and a modest heart rate rise of 10–20 bpm. Simultaneously, vagal (parasympathetic) output to the heart is withdrawn, allowing heart rate to increase. Within 30–60 seconds, blood pressure stabilises and heart rate settles.
In POTS, this compensatory mechanism overshoots or misfires. Heart rate climbs excessively and often remains elevated, producing symptoms: lightheadedness, palpitations, tremor, exercise intolerance, brain fog, nausea, and pre-syncope. True syncope (fainting) occurs in some patients but is not the defining feature — that distinguishes POTS from vasovagal syncope, where the problem is a sudden surge of vagal activity that drops both heart rate and blood pressure.
The Vagal Component of POTS
Heart rate variability (HRV) studies consistently show reduced vagal tone in POTS. A 2019 analysis in Autonomic Neuroscience examined 78 POTS patients and found significantly lower high-frequency HRV (the vagal marker) both at rest and during standing compared to age-matched controls. Reduced vagal tone means less parasympathetic braking on the heart, contributing to the exaggerated tachycardic response.
However, POTS is not simply “low vagal tone.” The condition has several recognised subtypes, each with different underlying mechanisms:
Neuropathic POTS involves partial autonomic denervation, particularly of sympathetic nerves to the lower extremities. Sweat testing and skin biopsies show reduced small-fibre nerve density in approximately 50% of POTS patients (a 2017 study in Neurology found reduced intraepidermal nerve fibre density in the legs of 37% of patients tested). Blood pools in the legs because sympathetic vasoconstriction is impaired. The heart compensates with excessive tachycardia.
Hyperadrenergic POTS features elevated standing noradrenaline levels (above 600 pg/mL) and can include hypertension rather than hypotension on standing. The vagal withdrawal is present but the primary driver is sympathetic over-activation. Some cases are associated with mast cell activation syndrome (MCAS) or noradrenaline transporter deficiency.
Hypovolaemic POTS involves reduced plasma and blood volume — studies have measured deficits of 10–20% compared to controls — reducing venous return and triggering compensatory tachycardia. Low renin-aldosterone activity and impaired renal sodium retention have been implicated.
Most patients have overlapping features. The vagus is involved in all subtypes through reduced cardiac parasympathetic tone, but it is rarely the sole problem.
Your local vagus nerve experts
Find a vagus nerve practitioner near you
Our directory lists 2,685 practitioners across the US, from polyvagal-informed therapists to HRV biofeedback clinics.
Or browse by approach
- HRV biofeedback
- Polyvagal-informed therapy
- Somatic therapy
- Craniosacral therapy
- Breathwork
- Insomnia therapy (CBT-I)
The directory covers the United States for now. Listings come from practitioners’ own websites and are not endorsements or medical advice. Browse the full directory.
POTS Triggers and Associations
POTS commonly develops after a viral infection, surgery, pregnancy, or concussion. Post-viral POTS received significant attention during the COVID-19 pandemic: a 2022 systematic review in Nature Reviews Cardiology reported that autonomic dysfunction meeting POTS criteria occurred in an estimated 2–14% of post-COVID patients, though many cases resolved within 6–12 months. The proposed mechanism involves autoimmune damage to autonomic ganglia or small fibres — autoantibodies against adrenergic and muscarinic receptors have been identified in a subset of POTS patients.
Ehlers-Danlos Syndrome (hypermobile type) and POTS frequently co-occur. Hypermobile connective tissue may allow excessive venous pooling, and shared genetic factors may predispose to both conditions. A 2020 study in the Journal of the American Heart Association found that 18% of POTS patients met criteria for hypermobile EDS, compared to roughly 1–2% in the general population.
Diagnosis
POTS is diagnosed by tilt-table testing or an active standing test showing a heart rate increase of 30 bpm or more (40 bpm in adolescents aged 12–19) within 10 minutes of upright posture, with symptoms, in the absence of orthostatic hypotension (a sustained blood pressure drop of more than 20/10 mmHg). Other causes of tachycardia — anaemia, hyperthyroidism, dehydration, pheochromocytoma, and medication effects — must be excluded.
Additional testing often includes 24-hour Holter monitoring, plasma catecholamines (supine and standing), autonomic reflex screening (Valsalva ratio, which directly tests vagal function), quantitative sudomotor axon reflex testing (QSART), and blood volume measurement. Reduced Valsalva ratio — a marker of impaired vagal cardiac control — is common in POTS.
Treatment
There is no single effective treatment for POTS, and management targets the specific subtype and dominant symptoms.
Volume expansion: Increased fluid intake (2–3 litres per day) and salt supplementation (6–10 grams per day, or salt tablets) help counter hypovolaemia. Fludrocortisone promotes renal sodium retention. Intravenous saline provides temporary relief for acute flares but is not a sustainable long-term strategy.
Exercise reconditioning: A structured, graduated exercise programme — beginning with recumbent exercises (rowing, swimming, recumbent cycling) and progressing to upright activity over 3–6 months — is the intervention with the strongest evidence. A 2021 randomised controlled trial in the Journal of the American College of Cardiology demonstrated that a 3-month supervised exercise programme eliminated POTS criteria in 71% of participants compared to 22% in the control group.
Compression: Waist-high compression garments (30–40 mmHg) reduce venous pooling. Abdominal binders can be more effective than lower-extremity stockings alone because the splanchnic circulation holds a large blood volume.
Medications: Beta-blockers (propranolol 10–20 mg, or ivabradine, which selectively reduces heart rate without lowering blood pressure) address tachycardia. Midodrine (an alpha-1 agonist) improves vasoconstriction. Pyridostigmine (an acetylcholinesterase inhibitor) enhances vagal and sympathetic ganglionic transmission and can reduce standing heart rate by 5–10 bpm. For hyperadrenergic POTS, clonidine or methyldopa may reduce sympathetic overactivity.
What About Vagus Nerve Stimulation?
Because reduced vagal tone is a feature of POTS, researchers have explored whether vagus nerve stimulation (VNS) could help. A 2020 pilot study in Frontiers in Neuroscience tested transcutaneous auricular VNS (taVNS) in 12 POTS patients and found modest reductions in standing heart rate and improvements in symptom scores over 2 weeks. However, the study was small, unblinded, and short-term. No large randomised trials of VNS for POTS have been published, and it is not a standard treatment. The strongest current evidence supports exercise reconditioning, volume expansion, and targeted pharmacotherapy.
POTS involves complex autonomic dysfunction that goes well beyond the vagus nerve alone. For a thorough guide to vagal anatomy, autonomic function, and evidence-based strategies for supporting your nervous system, get the Vagus Nerve & Me eBook.
